Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Denali Therapeutics (DNLI) Ownership - Who Owns Denali Therapeutics?
555 Followers
Denali Therapeutics (DNLI) Ownership Overview
38.97% Insiders
24.63% Mutual Funds
16.15% Other Institutional Investors
20.25% Public Companies and Individual Investors
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail and individual investors. Approximately 40.78% of the company’s stock is owned by Institutional Investors, 38.97% is owned by Insiders and 20.25% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Feb 15, 2024 | Steve E. Krognes Director | Sold | $47548 |
| Feb 15, 2024 | Ryan J. Watts President & Ceo,director | Sold | $165794 |
| Feb 15, 2024 | Alexander O. Schuth Cofo And Secretary | Sold | $46960 |
| Feb 15, 2024 | Carole Ho Cmo | Sold | $48135 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $58650 | |
| Dec 31, 2023 | Sold | $4240152 | |
| Dec 31, 2023 | Sold | $26168152 | |
| Dec 31, 2023 | Sold | $49786513 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,225,376 | Institution | 7.17% | 164,730,807 | |
| 9,199,215 | Institution | 6.45% | 148,199,354 | |
| 5,605,678 | Institution | 3.93% | 90,307,473 | |
| 5,100,454 | Institution | 3.58% | 82,168,314 | |
| 4,025,266 | Institution | 2.82% | 64,847,035 | |
| 3,702,237 | Institution | 2.60% | 59,643,038 | |
| 2,607,196 | Institution | 1.83% | 42,001,928 | |
| 2,512,759 | Institution | 1.76% | 40,480,547 | |
| 2,319,968 | Institution | 1.63% | 37,374,684 | |
| 1,261,678 | Institution | 0.89% | 20,325,633 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,199,215 | Institution | 6.45% | 148,199,354 | |
| 5,100,454 | Institution | 3.58% | 82,168,314 | |
| 4,025,266 | Institution | 2.82% | 64,847,035 | |
| 2,512,759 | Institution | 1.76% | 40,480,547 | |
| 1,261,678 | Institution | 0.89% | 20,325,633 | |
| 1,222,402 | Institution | 0.86% | 19,692,896 | |
| 1,197,891 | Institution | 0.84% | 19,298,024 | |
| 1,141,800 | Institution | 0.80% | 18,394,398 | |
| 1,020,500 | Institution | 0.72% | 16,440,255 | |
| 621,850 | Institution | 0.44% | 10,018,004 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,268,247 | Institution | 2.29% | 67,064,428 | |
| 3,560,627 | Institution | 2.50% | 57,361,701 | |
| 2,645,203 | Institution | 1.86% | 54,279,566 | |
| 2,829,537 | Institution | 1.99% | 45,583,841 | |
| 1,854,474 | Institution | 1.30% | 38,053,806 | |
| 1,496,785 | Institution | 1.05% | 30,714,028 | |
| 1,016,250 | Institution | 0.71% | 16,371,788 | |
| 841,242 | Institution | 0.59% | 13,552,409 | |
| 589,047 | Institution | 0.41% | 9,489,547 | |
| 446,182 | Institution | 0.31% | 9,155,655 |
FAQ
Who Owns Denali Therapeutics (DNLI)?
According to the latest TipRanks data, approximately 16.15% of the company's stock is held by institutional investors, 38.97% is held by insiders, and 20.25% is held by retail investors.
What percentage of Denali Therapeutics (DNLI) stock is held by institutional investors?
According to the latest TipRanks data, approximately 16.15% of Denali Therapeutics (DNLI) stock is held by institutional investors.
What percentage of Denali Therapeutics (DNLI) stock is held by retail investors?
According to the latest TipRanks data, approximately 20.25% of Denali Therapeutics (DNLI) stock is held by retail investors.
Who owns the most shares of Denali Therapeutics (DNLI)?
Vanguard owns the most shares of Denali Therapeutics (DNLI).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.